The recent evolution of therapeutic weapons against resistant Gram-positive microorganisms La evolución reciente de las armas terapéuticas contra los microorganismos Gram-positivos

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Unknown venue

• Publication date

  2008-12-01

• Fields of study

  Biology, Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Tigecycline: a novel glycylcycline antibiotic

  2006cited by this paper
• Daptomycin for the Treatment of Gram‐Positive Bacteremia and Infective Endocarditis: A Retrospective Case Series of 31 Patients

  2006cited by this paper
• Treatment Failure Resulting from Resistance of Staphylococcus aureus to Daptomycin

  2006cited by this paper
• Anticipating potential linezolid-SSRI interactions in the general hospital setting: an MAOI in disguise.

  2006cited by this paper
• Linezolid diminishes inflammatory cytokine production from human peripheral blood mononuclear cells.

  2006cited by this paper
• Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin.

  2006cited by this paper
• Glycopeptides: Update on an old successful antibiotic class.

  2006cited by this paper
• Infective endocarditis treated with linezolid: case report and literature review

  2006cited by this paper
• Dalbavancin: A New Option for the Treatment of Gram-Positive Infections

  2006cited by this paper
• Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.

  2006cited by this paper
• Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children

  2006cited by this paper
• Daptomycin: first in a new class of antibiotics for complicated skin and soft‐tissue infections

  2006cited by this paper
• The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.

  2006cited by this paper
• Drug Interactions Between Linezolid and Selective Serotonin Reuptake Inhibitors: Case Report Involving Sertraline and Review of the Literature

  2006cited by this paper
• Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis.

  2006cited by this paper
• In vivo synergy of daptomycin plus a penicillin agent for MRSA?

  2005cited by this paper
• Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents

  2005cited by this paper
• Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.

  2005cited by this paper
• Severe staphylococcal knee arthritis responding favourably to linezolid, after glycopeptide-rifampicin failure: A case report and literature review

  2005cited by this paper
• Mechanisms of action of newer antibiotics for Gram-positive pathogens.

  2005cited by this paper
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Tigecycline

  2005cited by this paper
• Tigecycline: what is it, and where should it be used?

  2005cited by this paper
• Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.

  2005cited by this paper
• Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance.

  2005cited by this paper
• Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.

  2005cited by this paper
• Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.

  2005cited by this paper
• Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds.

  2005cited by this paper
• Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.

  2005cited by this paper
• Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections

  2005cited by this paper
• Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection

  2005cited by this paper
• Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.

  2005cited by this paper
• Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy.

  2005cited by this paper
• New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient

  2005cited by this paper
• Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.

  2005cited by this paper
• The need for new therapeutic agents: what is the pipeline?

  2005cited by this paper
• Tigecycline: A review of a new glycylcycline antibiotic

  2005cited by this paper
• Current and emerging serious Gram-positive infections.

  2005cited by this paper
• Emergence of Staphylococcus hominis strains expressing low-level resistance to quinupristin/dalfopristin in Greece.

  2005cited by this paper
• In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates.

  2005cited by this paper
• Linezolid use associated with lactic acidosis

  2005cited by this paper
• Linezolid for the treatment of multidrug-resistant tuberculosis.

  2005cited by this paper
• Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.

  2005cited by this paper
• Population Pharmacokinetic Analysis of Dalbavancin, a Novel Lipoglycopeptide

  2005cited by this paper
• Linezolid treatment of ventriculoperitoneal shunt infection without implant removal

  2005cited by this paper
• Escalation of Antimicrobial Resistance among Streptococcus pneumoniae: Implications for Therapy

  2005cited by this paper
• Gram‐Positive Resistance: Pathogens, Implications, and Treatment Options Insights Society of Infectious Diseases Pharmacists

  2005cited by this paper
• Staphylococcal Skin Infections in Children

  2005cited by this paper
• The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

  2004cited by this paper
• Healthcare-associated pneumonia in adults: management principles to improve outcomes.

  2004cited by this paper
• Combining Quinupristin/Dalfopristin with Other Agents for Resistant Infections

  2004cited by this paper
• Peripheral neuropathy associated with prolonged use of linezolid.

  2004cited by this paper
• Daptomycin – a novel antibiotic against Gram-positive pathogens

  2004cited by this paper
• An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects.

  2004cited by this paper
• Antimicrobial resistance to linezolid.

  2004cited by this paper
• Evolution of the Antimicrobial Resistance of Staphylococcus spp. in Spain: Five Nationwide Prevalence Studies, 1986 to 2002

  2004cited by this paper
• Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate.

  2004cited by this paper
• A High Frequency of Macrolide-Lincosamide-Streptogramin Resistance Determinants in Staphylococcus aureus Isolated in South Korea

  2004cited by this paper
• Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.

  2004cited by this paper
• Oritavancin and Tigecycline: Investigational Antimicrobials for Multidrug‐Resistant Bacteria

  2004cited by this paper
• Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.

  2004cited by this paper
• Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology.

  2004cited by this paper
• A review of linezolid: the first oxazolidinone antibiotic

  2004cited by this paper
• Human intestinal bacteria as reservoirs for antibiotic resistance genes.

  2004cited by this paper
• Sensitivity of methicillin-resistant Staphylococcus aureus (MRSA) to antimicrobial agents other than beta-lactams: profile and trend, 1998-2003.

  2004cited by this paper
• The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species.

  2003cited by this paper
• Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies

  2003cited by this paper
• The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones.

  2003cited by this paper
• Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia.

  2003cited by this paper
• Risk Factors for Arthralgias or Myalgias Associated with Quinupristin‐Dalfopristin Therapy

  2003cited by this paper
• Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.

  2003cited by this paper
• Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin.

  2003cited by this paper
• Quinupristin-dalfopristin and linezolid: evidence and opinion.

  2003cited by this paper
• Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis.

  2003cited by this paper
• Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

  2003cited by this paper
• Novel antibacterial agents for the treatment of gram positive infections

  2003cited by this paper
• In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis That Are Susceptible or Resistant to First-Line Antituberculous Drugs

  2003cited by this paper
• Linezolid: The First Oxazolidinone Antimicrobial

  2002cited by this paper
• Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin.

  2002cited by this paper
• Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.

  2002cited by this paper
• Combination of Quinupristin/Dalfopristin and Glycopeptide in Severe Methicillin-Resistant Staphylococcal Infections Failing Previous Glycopeptide Regimens

  2002cited by this paper
• Treatment of Life-Threatening Multiresistant Staphylococcal and Enterococcal Infections in Patients with End-Stage Renal Failure with Quinupristin/Dalfopristin: Preliminary Report

  2002cited by this paper
• Synercid plus vancomycin for the Treatment of Severe Methicillin-resistant Staphylococcus aureus and Coagulase-negative Staphylococci Infections: Evaluation of 5 Cases

  2002cited by this paper
• Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin.

  2001cited by this paper
• Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

  2001cited by this paper
• Successful administration of quinupristin/dalfopristin in the outpatient setting.

  2001cited by this paper
• Erratum: Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecalis ventriculitis (Pharmacotheraphy (2001) 21:6 (748-750))

  2001cited by this paper
• Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

  2000cited by this paper
• Nosocomial bloodstream infections: organisms, risk factors, and implications.

  2000cited by this paper
• Experience with quinupristin/dalfopristin in treating infections with vancomycin‐resistant Enterococcus faecium in children

  2000cited by this paper
• Distribution and antibiotic resistance of isolates from lower respiratory tract and blood cultures from patients in three Italian intensive care units: a 2-year comparison.

  2000cited by this paper
• Vancomycin-resistant Enterococcus faecium infection in three children given allogeneic hematopoietic stem cell transplantation: clinical and microbiologic features.

  2000cited by this paper
• Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): case reports from the SENTRY antimicrobial surveillance program.

  2000cited by this paper
• Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin).

  2000cited by this paper
• Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature.

  2000cited by this paper
• Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

  1999cited by this paper
• Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.

  1999cited by this paper
• The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium

  1999cited by this paper
• Vancomycin-resistant Staphylococcus aureus: infection control considerations.

  1998cited by this paper
• Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.

  1998cited by this paper
• Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program.

  1998cited by this paper

• Preparation and evaluation of antibacterial wound dressing based on vancomycin-loaded silk/dialdehyde starch nanoparticles

  2022cites this paper
• Tipagem molecular de cepas de Enterococcus spp resistentes à vancomicina, isoladas em hospitais da cidade de São Paulo, no período de 1999 a 2008

  2011cites this paper